The Journal Join us Login
About Committee Program Keynote Speakers Location Accommodation Abstract Submissions Register
About Committee Program Keynote Speakers Location Accommodation Abstract Submissions Register
>Events Calendar > 4th Correlates of Protection for Next Generation Influenza Vaccines > Program

Program

ISRV has hosted a groundbreaking series of meetings dedicated to advancing the understanding of Correlates of Protection (CoP)—the immune responses that predict protection against respiratory virus infections. This series has brought together leading scientists, clinicians, regulatory experts, and industry representatives to discuss progress, challenges, and opportunities in defining immune correlates for influenza and SARS-CoV-2 to guide next generation vaccine development and evaluation.

View the program

About the Series:

The ISRV Correlates of Protection meetings aim to:

  • Foster international collaboration and knowledge exchange on CoPs
  • Explore advances in immunological assays and biomarkers
  • Discuss regulatory and clinical implications of CoPs
  • Guide influenza vaccine development and evaluation strategies

Each meeting in the series focused on a blend of cutting-edge science and applied regulatory discussions, creating a platform for translating laboratory insights into actionable vaccine development strategies.

Meeting Locations & Highlights

Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines. Miami, USA (2010)

The inaugural ISRV CoP meeting set the foundation for the series. This meeting addressed the critical need for harmonized approaches to identifying and validating CoPs to support licensure of seasonal and pandemic vaccines—particularly in the context of novel vaccine technologies.

Key highlights:

  • Lessons from 2009 H1N1 pandemic:
  • Review of immunological mechanisms of protection
  • Regulatory challenges associated with non-traditional vaccines
  • Importance of standardizing and harmonizing immunoassays
  • Collaborative action needed to develop and validate assays

Meeting report
https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1750-2659.2011.00242.x

Immunological assays and correlates of protection for next-generation influenza vaccines
Siena, Italy (2019)

This meeting was held in the historic city of Siena focusing on the evolving landscape of influenza vaccine development.

Key highlights

  • Value of CoPs for vaccine development: target discovery and de-risking of product development
  • Immunological assays: from research to clinical trials
  • Harmonization and Standardization of assays
  • CoPs and animal models
  • Human studies to define novel C0Ps
  • Regulatory pathways for vaccine licensure

Link to meeting report https://onlinelibrary.wiley.com/doi/10.1111/irv.12706

Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID‐19 Pandemic
Seattle, USA (2023)

The Seattle meeting reviewed the lessons learned from the COVID-19 pandemic and the use of transformational vaccine platforms and developmental processes to inform the way forward to identify and validate new immune CoPs against influenza for accelerated development of improved influenza vaccines.

Key themes:

  • Lessons from COVID-19 vaccine platforms
  • Mucosal, B and T cellular immunity
  • Strategies to identify and validate new immune correlates of protection
  • Epidemiology of respiratory viruses and study design
  • Lessons From International Consortia Assay standardization and harmonization
  • Regulatory aspects of Next Generation/Universal Influenza Vaccines

Read the meeting report

Collaborative Impact

The CoP series has catalysed important cross-sectoral collaborations between academia, industry and regulators laying the groundwork for future use of immune COPs in vaccine approval processes. ISRV continues to serve as a convener of this critical dialogue, aligning scientific innovation with regulatory and public health priorities.